Company profile: Milestone Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of small-molecule therapeutics for cardiovascular diseases, including Etripamil, a nasal spray calcium channel blocker in development for the acute treatment of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), and OutsmartPSVT.com, a website to help patients and caregivers manage PSVT with their healthcare team.
Products and services
- Etripamil: A small-molecule nasal spray calcium channel blocker being developed for the acute treatment of PSVT and atrial fibrillation with rapid ventricular rate (AFib-RVR)
- Cardiovascular Drug Development: Develops small-molecule therapeutics for the treatment of cardiovascular diseases as the company’s core activity
- OutsmartPSVT.com: A web-based resource created to help patients and caregivers manage paroxysmal supraventricular tachycardia (PSVT) in partnership with their healthcare team
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Milestone Pharmaceuticals
Proxim Diagnostics
HQ: United States
Website
- Description: Provider of next-generation handheld immunodiagnostic solutions, including a portable device for near-patient whole blood testing with touch-screen and multiple connectivity options, low-cost disposable test cartridges, and a test menu for sepsis, cardiology, and infectious disease (e.g., PCT). Suitable for emergency rooms, ICU, nursing and home care, community and employee clinics, rural and remote clinics, disaster relief, and defense.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proxim Diagnostics company profile →
3F Therapeutics
HQ: United States
Website
- Description: Provider of cardiovascular devices and invasive and transapical aortic heart replacement technology, including enabling aortic heart valve, entrata aortic valve system, and endurance valve system, to reduce surgical cross-clamp and cardio-pulmonary bypass time, with utilization for congestive heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 3F Therapeutics company profile →
Apama Medical
HQ: United States
Website
- Description: Provider of medical devices for the electrophysiology (EP) market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apama Medical company profile →
Hemostemix
HQ: Canada
Website
- Description: Provider of autologous cell therapies derived from a patient's own blood, including ACP-01 to regenerate blood flow and tissue for ischemic conditions such as critical limb ischemia, peripheral arterial disease, angina, and ischemic cardiomyopathy, and NCP-01, a neuronal cell precursor therapy aimed at treating central and peripheral nervous system conditions including neuropathic pain, spinal cord injuries, and stroke.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hemostemix company profile →
Genetesis
HQ: United States
Website
- Description: Provider of medical imaging leveraging data science and biomagnetism for cardiovascular disease, offering CardioFlux, a non-invasive cardiac imaging system that measures the magnetic fields generated by the heart's electrical activity to assess myocardial ischemia and microvascular function, and the MAGNETO Trial, a multicenter, prospective, observational cohort study evaluating the diagnostic performance of MCG versus standard noninvasive stress testing in emergency department patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genetesis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Milestone Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Milestone Pharmaceuticals
2.2 - Growth funds investing in similar companies to Milestone Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Milestone Pharmaceuticals
4.2 - Public trading comparable groups for Milestone Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →